Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 15,000 shares of the stock in a transaction that occurred on Wednesday, April 7th. The shares were sold at an average price of $72.81, for a total value of $1,092,150.00.
Daniel Bradbury also recently made the following trade(s):
- On Wednesday, March 24th, Daniel Bradbury sold 7,500 shares of Castle Biosciences stock. The shares were sold at an average price of $63.09, for a total transaction of $473,175.00.
- On Tuesday, February 23rd, Daniel Bradbury sold 7,500 shares of Castle Biosciences stock. The stock was sold at an average price of $79.63, for a total value of $597,225.00.
- On Wednesday, February 10th, Daniel Bradbury sold 15,000 shares of Castle Biosciences stock. The stock was sold at an average price of $95.35, for a total value of $1,430,250.00.
- On Monday, January 25th, Daniel Bradbury sold 7,500 shares of Castle Biosciences stock. The shares were sold at an average price of $76.94, for a total transaction of $577,050.00.
- On Tuesday, January 12th, Daniel Bradbury sold 12,113 shares of Castle Biosciences stock. The shares were sold at an average price of $78.29, for a total transaction of $948,326.77.
Shares of Castle Biosciences stock traded up $0.22 on Thursday, hitting $70.76. The stock had a trading volume of 161,532 shares, compared to its average volume of 318,694. The company has a current ratio of 6.65, a quick ratio of 6.59 and a debt-to-equity ratio of 0.07. The company's 50 day moving average price is $71.50 and its 200 day moving average price is $64.11. Castle Biosciences, Inc. has a 52-week low of $26.13 and a 52-week high of $107.69. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -420.50 and a beta of 0.46.
Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Sunday, March 7th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by ($0.12). Castle Biosciences had a negative return on equity of 2.69% and a negative net margin of 5.30%. The firm had revenue of $17.30 million for the quarter, compared to analysts' expectations of $15.74 million. During the same period last year, the firm earned $0.11 EPS. Castle Biosciences's revenue was down 1.9% compared to the same quarter last year. Analysts predict that Castle Biosciences, Inc. will post -0.4 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of Castle Biosciences by 21.6% in the third quarter. BlackRock Inc. now owns 999,662 shares of the company's stock valued at $51,433,000 after purchasing an additional 177,685 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Castle Biosciences by 6.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,703 shares of the company's stock worth $345,000 after purchasing an additional 396 shares during the last quarter. State Street Corp lifted its stake in Castle Biosciences by 11.4% in the 3rd quarter. State Street Corp now owns 208,120 shares of the company's stock valued at $10,708,000 after buying an additional 21,262 shares in the last quarter. UBS Asset Management Americas Inc. grew its holdings in Castle Biosciences by 57.9% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 259,137 shares of the company's stock valued at $13,333,000 after buying an additional 95,058 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Castle Biosciences by 268.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 85,526 shares of the company's stock worth $4,401,000 after buying an additional 62,304 shares in the last quarter. 66.42% of the stock is currently owned by institutional investors.
A number of equities analysts have recently weighed in on the company. KeyCorp increased their price target on Castle Biosciences from $70.00 to $90.00 and gave the stock an "overweight" rating in a report on Wednesday, February 3rd. SVB Leerink boosted their price target on shares of Castle Biosciences from $70.00 to $80.00 and gave the company an "outperform" rating in a research note on Friday, January 15th. Zacks Investment Research cut shares of Castle Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday, March 11th. Robert W. Baird cut their target price on Castle Biosciences from $87.00 to $82.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 9th. Finally, BTIG Research raised their price target on Castle Biosciences from $60.00 to $80.00 and gave the stock a "buy" rating in a research report on Thursday, December 17th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has an average rating of "Buy" and a consensus price target of $79.50.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Further Reading: Holder of Record
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]7 Sports Betting Stocks That Will Shine Beyond March Madness
One of the many consequences of the novel coronavirus was the shutdown of live sports. For sports-minded individuals, one of the events that were missed the most was the NCAA Basketball Tournament affectionately known as March Madness.
But in addition to missing the entertainment that sports provide, cities and states realized, if they didn’t already, that sports are an economic necessity.
Live sports may also be a key to their post-pandemic future. But this goes beyond hotels and restaurants.
Sports betting has become big business. Currently, 25 states and the District of Columbia have legalized sports betting either by statute or by ballot initiative. That list is likely to grow. Many states face budget deficits and want to legalize sports betting for the revenue that it could receive.
And this is about more than allowing gamblers to place bets via a sportsbook in a casino. The real driver for this is mobile sports betting. According to the American Gaming Association, over 47 million people are expected to place bets during the NCAA basketball tournament, with approximately one-third of those bets (17.8 million) being placed online.
To help you take advantage of this still-emerging trend, we’ve put together this special presentation. Here we’ll highlight seven sports betting stocks that should generate significant revenue during March Madness and beyond.
View the "7 Sports Betting Stocks That Will Shine Beyond March Madness"